Reuters logo
BRIEF-Athenex announces positive recommendations from the ‍DSMB to continue the oraxol phase iii program
2017年10月5日 / 中午12点26分 / 19 天内

BRIEF-Athenex announces positive recommendations from the ‍DSMB to continue the oraxol phase iii program

Oct 5 (Reuters) - Athenex Inc

* Athenex announces positive recommendations from the Drug Safety Monitoring Board to continue the oraxol phase iii program

* Athenex Inc - ‍DSMB encouraged rapid patient recruitment toward scheduled second interim analysis at 180 patients​

* Athenex Inc - ‍DSMB unanimously recommended continuation of oraxol phase iii study​

* Athenex Inc - ‍adverse event of painful neuropathy was “uncommon” with oraxol treatment​

* Athenex Inc - expect clinical trial to proceed on track with rapid patient recruitment timelines & scheduled second interim analysis at 180 patients in 2018​

* Athenex Inc - ‍expect trial to proceed on track with scheduled second interim analysis at 180 patients in 2018​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below